Literature DB >> 16248282

Gene therapy for type 1 diabetes: a proposal to move to the next level.

Nick Giannoukakis1, Massimo Trucco.   

Abstract

A number of studies have confirmed that gene therapy can be successfully applied to prevent type 1 diabetes mellitus and to facilitate the transplantation of replacement insulin-producing cells as allografts of the islets of Langerhans or in the form of enriched and homogeneous surrogate cells. However, these successes have remained restricted to a few rodent models and have not progressed past this stage into larger animals. Newer technology has also emerged that offers exciting alternatives or complementary methods to achieve the same results, including therapeutic cloning. A synopsis of the strategies and tools used successfully in vivo is provided and a proposal to motivate a step-up of these approaches to larger animals, if not outright to safety trials in humans, is outlined. Additionally, newer emerging technologies that can, in the future, complement those that are currently readily adaptable to clinical implementation are suggested.

Entities:  

Mesh:

Year:  2005        PMID: 16248282

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  3 in total

1.  Protection against autoimmune diabetes by silkworm-produced GFP-tagged CTB-insulin fusion protein.

Authors:  Qiaohong Meng; Wenfeng Wang; Xiaowen Shi; Yongfeng Jin; Yaozhou Zhang
Journal:  Clin Dev Immunol       Date:  2011-06-06

2.  Induction of insulin secretion in engineered liver cells by nitric oxide.

Authors:  Latha Muniappan; Sabire Ozcan
Journal:  BMC Physiol       Date:  2007-10-17

3.  Nonvirally modified autologous primary hepatocytes correct diabetes and prevent target organ injury in a large preclinical model.

Authors:  Nelson K F Chen; Jen San Wong; Irene H C Kee; Siang Hui Lai; Choon Hua Thng; Wai Har Ng; Robert T H Ng; Soo Yong Tan; Shu Yen Lee; Mark E H Tan; Jaichandran Sivalingam; Pierce K H Chow; Oi Lian Kon
Journal:  PLoS One       Date:  2008-03-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.